Nasdaq auph.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Q3 2023 Earnings Call Transcript November 2, 2023 Aurinia Pharmaceuticals Inc. beats earnings expectations. …

Nasdaq auph. Things To Know About Nasdaq auph.

Swiss National Bank raised its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 7.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).The firm owned 279,300 shares of the biotechnology company’s stock after acquiring an …Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Q3 2023 Earnings Call Transcript November 2, 2023 Aurinia Pharmaceuticals Inc. beats earnings expectations. …ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and nine months ended September 30, 2023.Amounts are expressed in U.S. dollars. Net product revenue was $40.8 million for the three months ended …Within the last quarter, Aurinia Pharmaceuticals (NASDAQ:AUPH) has observed the following analyst ratings: Menu icon A vertical stack of three evenly spaced horizontal lines.

AUPH Stock Overview. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. About the company. AUPH fundamental analysis.Track Aurinia Pharmaceuticals Inc (AUPH) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsNASDAQ: AUPH Aurinia Pharmaceuticals. Market Cap. $1B. Today's Change (1.44%) $0.13. ... (AUPH 1.44%), a company focused on developing treatments for autoimmune diseases, saw its share price fall ...

Aurinia Pharmaceuticals (NASDAQ: AUPH), in its third-quarter earnings call for 2023, reported a significant increase in net product revenue and ongoing expansion efforts, while also revealing that ...Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) value has fallen 11% in the last week, but insiders who sold US$32m worth of stock over the last year have had less success. Insiders would probably ...

SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) securities between May 7 ...Last month, AUPH's second largest shareholder, MKT Capital, which holds 4.2% of the stock, wrote a scathing letter to shareholders, calling to withdraw support for CEO Peter Greenleaf, board ...Aurinia Pharmaceuticals (NASDAQ: AUPH), in its third-quarter earnings call for 2023, reported a significant increase in net product revenue and ongoing expansion efforts, while also revealing that ...Dec 1, 2023 · View Aurinia Pharmaceuticals Inc AUPH investment & stock information. Get the latest Aurinia Pharmaceuticals Inc AUPH detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Aurinia Pharmaceuticals Inc. (AUPH) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 9.06 +0.42 (+4.86%) At close: 04:00PM EST 8.94 -0.12 ( …

Aurinia Pharmaceuticals ( AUPH 3.43%), a small-cap commercial-stage drugmaker, is having another strong session today. Specifically, the biotech's stock was up by 11.9% on moderate volumes as of 1 ...

NASDAQ: AUPH Aurinia Pharmaceuticals. Market Cap. $1B. Today's Change (1.44%) $0.13. ... (AUPH 1.44%), a company focused on developing treatments for autoimmune diseases, saw its share price fall ...About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.Principal Financial Group Inc. cut its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 8.4% in the 2nd quarter, according to its most recent filing with the ...We feel now is a pretty good time to analyse Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) business as it appears the company may be on the cusp of a considerable accomplishment. Aurinia ...Aurinia Pharmaceuticals (NASDAQ: AUPH) reversed an earlier decline and is now up 3.4% after a report indicated Biogen (NASDAQ: BIIB) could potentially look to target the company. Aurinia ( AUPH ...

Aurinia Pharmaceuticals Price Performance Shares of NASDAQ AUPH opened at $9.06 on Monday. The company has a current ratio of 5.77, a quick ratio of …Cramer said Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a Canadian company that "I don’t really have a lot of confidence in, and I’m not recommending any companies that are losing money hand ...Aurinia Pharmaceuticals ( NASDAQ: AUPH) named Dr. Robert Foster as a new board member Thursday as part of an agreement with its major shareholder and investment management firm, MKT Capital Ltd ...VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on ...Dec 3, 2021 · Shares of Aurinia Pharmaceuticals Inc. AUPH gained 13.2% on Dec 2, following fresh rumors of a potential buyout. Reportedly, Swiss pharma giant Novartis NVS is looking out for small bolt-on ... 9. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Burrage Capital owned just over 362,000 shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) on September 30 and was more bullish on the stock during ...

Big Biotech Stocks to Buy Under $10 #4: Aurinia Pharmaceuticals (AUPH) Source: Aurinia. Share Price: $5.46. Lupus remains one of the least understood auto-immune diseases. With lupus, the body’s ...Dec 3, 2021 · Shares of Aurinia Pharmaceuticals Inc. AUPH gained 13.2% on Dec 2, following fresh rumors of a potential buyout. Reportedly, Swiss pharma giant Novartis NVS is looking out for small bolt-on ...

NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ...Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancinAldeyra Therapeutics Inc (NASDAQ:ALDX) has a beta value of 1.43 and has seen 0.58 million shares traded in the recent trading session. The company, currently valued at $177.64M, closed the recent trade at $3.02 per share which meant it gained $0.16 on the day or 5.59% during that session. ... (NASDAQ:AUPH) has a beta value of 1.39 and has …Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s traded shares stood at 0.69 million during the latest session, with the company’s beta value hitting 1.28. At the last check today, the stock’s price was $9.28, to imply an increase of 2.66% or $0.24 in intraday trading.NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.To wit, the Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) share price is 78% higher than it was a year ago, much better than the market return of around 12% (not …The public float for AUPH is 130.54M, and currently, shorts hold a 13.23% of that float. The average trading volume for AUPH on November 16, 2023 was 1.69M shares. AUPH) stock’s latest price update. The stock price of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has dropped by -0.12 compared to previous close of 8.17.NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...

The company has $337.90 million in cash and $93.21 million in debt, giving a net cash position of $244.69 million or $1.70 per share. Cash & Cash Equivalents.

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for third ...

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Aurinia Pharmaceuticals (NASDAQ: AUPH) on Friday, setting a price target of $35, which is approximately 142.38% above the present share ...Jun 30, 2023 · NASDAQ: AUPH Aurinia Pharmaceuticals. Market Cap. $1B. Today's Change (2.09%) $0.18. Current Price. ... (AUPH 2.09%) rose by as much as 13.2% in early morning trading Friday. The biotech's shares ... NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ... Aurinia Pharma (NASDAQ: AUPH) shares quickly jumped to a session high, triggering a volatility halt after Bloomberg reported a potential bid from Bristol Myers Squibb (NYSE: BMY) to acquire the ...NASDAQ:AUPH. Press Releases. May 17, 2023. Aurinia Announces 2023 Annual General Meeting Results May 09, 2023. Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS ...Jun 30, 2023 · June 30, 2023 — 02:07 pm EDT. Below is Validea's guru fundamental report for AURINIA PHARMACEUTICALS INC ( AUPH). Of the 22 guru strategies we follow, AUPH rates highest using our Value Investor ... During the last session, Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s traded shares were 2.07 million, with the beta value of the company hitting 1.26. At the end of the trading day, the stock’s price was $8.64, reflecting an intraday gain of 0.47% or $0.04. The 52-week high for the AUPH share is ...Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH): Supportive interim analysis of its AURORA 2 Phase 3 continuation study that is evaluating Lupkynis for the treatment of lupus nephritis.

Aurinia Pharmaceuticals (NASDAQ:AUPH) is a biopharmaceutical firm delivering therapies for autoimmune, kidney, and rare diseases with unmet medical needs. In 2021, it introduced Lupkynis ...Sep 15, 2023 · 8.82%. 141,687,578. 12,497,875. 1,990,667. 6.28. Data brought to you by Benzinga APIs. Looking for the most shorted stocks? Short interest for Aurinia Pharmaceuticals gives investors a sense of ... Aurinia Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AUPH) $8.60 -0.09 (-1.04%) (As of 11/29/2023 ET) Compare Today's Range $8.54 $8.99 50-Day …Nov 15, 2023 · Below is a chart showing AUPH's trailing twelve month trading history, with the $9 strike highlighted in orange: Phillips 66 (Symbol: PSX) options are showing a volume of 21,547 contracts thus far ... Instagram:https://instagram. autozone temubanks stockzillow group stocktoday's highest stock gainers (NASDAQ: AUPH) Aurinia Pharmaceuticals currently has 143,608,164 outstanding shares. With Aurinia Pharmaceuticals stock trading at $8.23 per share, the total value of Aurinia Pharmaceuticals stock (market capitalization) is $1.18B .9. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Burrage Capital owned just over 362,000 shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) on September 30 and was more bullish on the stock during ... dilar treeford stock dividend history Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results Business Wire - Thu May 4, 5:00AM CDT. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars. 9.28. occidental petroleum dividend AUPH Inverse H&S Price has broken out of a down channel I see this breaking down slightly back into the channel, forming a right shoulder along the yellow horizontal and then continuing to pursue the reversal above the channel Lets see what happens on this Weekly chart Bars pattern in green shows my idea Price has broken out of a down channel I see this breaking down slightly back into the ...Aurinia Pharmaceuticals ( AUPH 3.43%), a small-cap commercial-stage drugmaker, is having another strong session today. Specifically, the biotech's stock was up by 11.9% on moderate volumes as of 1 ...